Drug recall · March 3, 2021
MethyIPREDNISolone Acetate Injectable Suspension USP recall
Why: Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
MethyIPREDNISolone Acetate Injectable Suspension USP, 400 mg/5 mL (80 mg/mL), 5 mL Multiple-Dose Vial, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0703-0063-01.
- Lots / codes
Lot # 31327738B, exp. date 03/2021
- Quantity
- 15,043 vials
- Company
- Teva Pharmaceuticals USA, Parsippany, NJ
- Distribution
- Product was distributed nationwide in the USA and Puerto Rico.
- Initiated
- February 10, 2021 · Voluntary: Firm initiated
- Classified
- February 21, 2021
- Reported
- March 3, 2021
- Ended
- May 15, 2024
- How notified
- Letter
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.